June 11 (Reuters) - Biopharmaceutical company Dynavax

Technologies ( DVAX ) on Wednesday defeated investment firm Deep

Track Capital's effort to unseat directors when investors

re-elected all four candidates, the company said.

Deep Track, Dynavax's ( DVAX ) second-largest shareholder with a

nearly 15% stake, mounted a proxy fight to elect new directors

who would prioritize development of the company's hepatitis B

vaccine instead of pursuing new acquisitions.

The investment firm nominated one of its executives and

three people with industry expertise as candidates to replace

the four directors who are standing for the election this year.